Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer

SAR125844 is a potent and selective inhibitor of the c-Met kinase receptor. This was an open-label, phase I, multicenter, dose-escalation, and dose-expansion trial of SAR125844 in Asian patients with solid tumors, a subgroup of whom had gastric cancer and MET amplification (NCT01657214). SAR125844 w...

Descripción completa

Detalles Bibliográficos
Autores principales: Shitara, Kohei, Kim, Tae Min, Yokota, Tomoya, Goto, Masahiro, Satoh, Taroh, Ahn, Jin-Hee, Kim, Hyo Song, Assadourian, Sylvie, Gomez, Corinne, Harnois, Marzia, Hamauchi, Satoshi, Kudo, Toshihiro, Doi, Toshihido, Bang, Yung-Jue
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Clinical Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668067/
https://www.ncbi.nlm.nih.gov/pubmed/29108334
http://dx.doi.org/10.18632/oncotarget.18554

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5668067/
https://www.ncbi.nlm.nih.gov/pubmed/29108334
http://dx.doi.org/10.18632/oncotarget.18554

Ejemplares similares